Ocugen, Inc. (OCGN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US67577C1053
Ocugen, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 4.41 m USD |
| Operating income | -62.92 m USD |
| EBIT | -63.58 m USD |
| Net income | -67.85 m USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Ocugen, Inc.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
More stocks
- V Zug Holding Ag (VZUG.SW)
- PI Advanced Materials Co. Ltd (178920.KS)
- Dongnan Electronics Co. Ltd. A (301359.SZ)
- Nanjing Wondux Environmental Protection Technology Corp Ltd (688178.SS)
- KINGSTONE COMPANIES, INC. (KINS)
- Shandong Sito Bio-technology Co Ltd (300583.SZ)
- Hualan Group Co Ltd (301027.SZ)
- LCY Technology Corp (4989.TW)
- ExaWizards Inc (4259.T)
- Jiangsu Wanlin Modern Logistic (603117.SS)
- Wuxi Honghui New Materials Technology Co Ltd (002802.SZ)
- Jiangsu Cowin Biotech Co. Ltd. A (688426.SS)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.